Uncategorized Archives - Page 11 of 87 - PsychedelicNewsWire (PNW)

ThursdayMar 24, 2022 9:15 am

Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Is a Leader in Psychedelic-Based Therapies; Recent Preclinical Research Shows Treatment Effective for MDD

Study shows that substantial antidepressant effects of psilocybin-based treatment, given with supportive psychotherapy, may last at least a year. Psilocybin could lead to significant, durable improvements in depression. Cybin is focused on improving overall mental health through psychedelic-based therapies. Johns Hopkins Medicine researchers have released a report noting that psilocybin treatment for major depression is effective for up to a year for many patients (https://ibn.fm/ZF8jH). That bodes well for Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company that is focused on revolutionizing mental health care, including major depressive disorder (“MDD”). “Previous studies by Johns Hopkins Medicine researchers…

FridayMar 18, 2022 9:15 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Offers a Glimpse into its R&D Pipeline, Patent Strategies, and Clinical Trials at March Investor Conferences

Mydecine participated in this year’s Annual Roth Conference, the Oppenheimer & Co. Annual Healthcare Conference, and will be at the upcoming Maxim Group’s Virtual Growth Conference These conferences represent an opportunity for the company to share its R&D pipeline, patent strategies and ongoing clinical trials Mydecine’s management has optimism for the future, as it taps into the growing psychedelics therapeutics and smoking cessation markets Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) has been at the forefront of developing novel psychedelic and non-psychedelic molecules for medical use. Its research and development efforts have focused on compounds that can enable safer and…

ThursdayMar 17, 2022 9:15 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Aiming to Reach Millions of Mental Health Patients with Effective, Affordable Ketamine Treatments

Mental health conditions affect millions of people globally, some of whom are resistant to existing treatments In the early 1990s, Yale researchers discovered that ketamine offered immediate relief to chronically depressed patients, and since then, the scientists have continually investigated the compound’s role in mental health treatment Delic’s subsidiary, Ketamine Wellness Centers, notes that ketamine is now extensively used for multiple treatment-resistant mental conditions, with patient outcomes showing its therapeutic effectiveness Delic hopes to reach millions of people suffering from various mental health conditions who have lost hope of finding effective, affordable treatments The World Health Organization (“WHO”) reports that…

ThursdayMar 17, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) on Leading Edge of Development of Psychedelics as Public Support Grows

More than 60% of American who suffer from mental health conditions want access to psychedelic options Growing number of cities, states looking at decriminalizing use of psychedelic medicine Cybin is working with world-class partners, internationally recognized scientists to create safe, effective therapeutics in the mental-health space The awareness of psychedelics and the potential for treating an array of mental health diseases is growing, as evidenced by a recent survey reporting that 65% of affected Americans want access to psychedelics for potential treatment (https://ibn.fm/jIV2K). Those are numbers that Cybin (NEO: CYBN) (NYSE American: CYBN), a leading ethical biopharmaceutical company, is paying close attention…

WednesdayMar 16, 2022 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Leverages Research to Promote Mental Health

Delic Holdings Corp, a leader in new medicines and treatments for a modern world, understands that research is integral for both the rapidly developing psychedelics and cannabis industries, and for psychedelics to be widely adopted for the treatment of mental health issues Dr. Markus Roggen, President and CSO of Delic Labs, recently spoke at this year’s Emerald Conference, and has reiterated the importance of leveraging AI in crafting products for the cannabis industry Delic is continually expanding its efforts to conduct and encourage even more research and education in support of high-quality products for more people, supporting mental health while…

FridayMar 11, 2022 10:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Reports Positive Pre-IND Meeting with FDA, Changes to Its Clinical Trial Approach; Plans Breakthrough Therapy Designation Request for MYCO-001

Mydecine recently reported a positive Pre-IND meeting with the FDA for the MYCO-001 smoking cessation study According to the Center for Disease Control (“CDC”), tobacco is the leading cause of preventable deaths in the U.S. Following the FDA meeting, the company now intends to perform a Phase 2b study and then a Phase 3 study instead of a seamless Phase 2/3 clinical trial Mydecine plans to submit a request for breakthrough therapy status with its IND submission Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) has continually taken steps toward fulfilling its mission to become a trusted source of safe and…

MondayMar 07, 2022 11:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Chopra Foundation Partner in Efforts to Support Progress Toward Psychedelic-Based Therapeutics

Psychedelic drugs are on cusp of entering mainstream treatment for mental illness Cybin, Chopra Foundation to collaborate on efforts aimed to support education, awareness about psychedelic therapy mental health research Cybin “one of the only companies that may truly address the needs of patients and providers,” says Dr. Deepak Chopra A significant increase in research and growing public support are key indicators of the future of psychedelics, which are “on the cusp of entering mainstream psychiatry,” according to a recent “New York Times” article (https://ibn.fm/GshwS). Another strong indicator of the future of psychedelics is the exciting partnership just announced by…

ThursdayMar 03, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Granted U.S. Patent for Deuterated DMT

Company announced the first officially issued patent Patent provides strong protection for Cybin’s growing IP portfolio of psychedelic-based compounds CYB004 has demonstrated potential efficacy at lower doses while increasing duration of drug effect that may alleviate common negative experiences In a milestone moment for psychedelic therapeutics company Cybin (NEO: CYBN) (NYSE American: CYBN), the company has announced its first official issued patent. The U.S. Patent and Trademark Office (“USPTO”) has granted U.S. patent 11,242,318 to Cybin’s proprietary CYB004, the company’s lead investigational proprietary DMT compound. “From the outset, Cybin has focused on creating differentiated compounds that harness the potential efficacy of…

MondayFeb 28, 2022 9:45 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Tackles Pandemic-era Mental Health Crises with Product R&D and Educational Efforts for the Application of Psychedelics Technology

Delic Holdings Corp is a leader in new medicines and treatments for a modern world with a focus on improving access to health benefits across the country through an integrated, scalable approach to meeting patients’ mental wellness needs Delic has built a three-pronged ecosystem that includes Ketamine Wellness Centers (“KWC”), the largest chain of wellness clinics providing ketamine treatments in the U.S.; Reality Sandwich and Meet Delic, media properties providing education on psychedelics; and DELIC Labs, a federally-authorized research facility The company’s CSO has spoken at a number of conferences on the importance of controlling the extraction production processes for…

MondayFeb 28, 2022 9:15 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Makes Exciting Drug Discovery for the Treatment of Mental health and Addiction Disorders – MYCO-005

Mydecine announced the inclusion of a patent-pending novel molecule in its family of psilocin analogs, MYCO-005 This molecule features potentially heart-safe microdose-enabling properties, addressing the delivery and stability concerns associated with the first-generation compounds Mydecine’s patent-pending dermal route to administration also offers more control over the drug while possibly eliminating undesirable properties such as nausea The company is excited about this finding, terming it one of the many exciting drug discoveries it looks to share in the near term Microdosing, the act of consuming a minimal dose of a psychedelic to benefit from what it offers without going through a…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Uncategorized